A newly appointed CDC advisory group is launching reviews of key childhood vaccine guidelines, sparking concern from medical experts and pediatricians across the U.S.
Why the Panel Was Replaced
Health Secretary Robert F. Kennedy Jr. recently dismissed the CDC’s 17-member vaccine advisory committee, citing conflicts of interest. He replaced them with a new group of eight members—one later withdrew, leaving seven.
Critics argue the move was politically driven and undermines scientific integrity. Several new members have previously testified against vaccines or questioned their safety without scientific backing.
What the New Panel Plans to Review
1. Vaccine Schedule for Kids and Teens
The panel will examine possible cumulative effects of vaccines, how different vaccines interact, and whether their timing could be adjusted.
2. Hepatitis B at Birth
The committee will revisit whether all newborns should get the hepatitis B shot. They’re considering delaying it unless the mother is infected.
Medical experts warn this could risk missed infections and unnecessary illness.
3. Measles, Mumps, Rubella & Chickenpox Combo Vaccine
They may review the combined four-in-one shot given to toddlers, which carries a slightly higher risk of fever-related seizures. Alternatives, like separate doses or Japan’s model, will be discussed.
What Doctors Are Saying
Pediatricians and vaccine researchers say these vaccines have already been thoroughly studied for safety and effectiveness.
Dr. Paul Offit, a vaccine expert, called the committee’s direction a “purely anti-vaccine agenda.”
The American Academy of Pediatrics has now pulled out of participating in the meetings. Its president said the process has “lost credibility.”
What’s at Stake
The CDC’s vaccine guidance affects insurance, school policies, and public trust. Changes could influence how millions of children receive immunizations.
As measles cases rise in the U.S.—with over 1,200 this year—many experts warn against stepping back from proven vaccine strategies.
RSV Decision Delayed
A scheduled vote on a new RSV antibody for infants, called clesrovimab (brand name Enflonsia), was postponed due to time constraints. The drug was FDA-approved earlier this month and could help protect babies during RSV season.
Conclusion
Vaccines have long been the backbone of child health in the U.S. Experts caution that changing vaccine policies must be driven by science—not politics. As the new panel moves forward, public health leaders urge transparency and evidence-based decisions.
Related topics:
